No Data
No Data
Zhejiang Qianjiang Biochemical's semi-annual report for 2024.
Zhejiang Qianjiang Biochemical 2024 Interim Report Summary
Zhejiang Qianjiang Biochemical (600796.SH): The net income for the first half of the year was 0.082 billion yuan, a decrease of 2.62% compared to the same period last year.
Zhejiang Qianjiang Biochemical (600796.SH) announced its semi-annual report on August 26th. During the reporting period, the company's consolidated revenue was 0.863 billion yuan, a decrease of 0.55% compared to the same period last year. The net income attributable to shareholders of the listed company was 0.082 billion yuan, a decrease of 2.62% year-on-year. Among them, the revenue from eco-friendly businesses was 0.422 billion yuan, accounting for 48.90% of the revenue, an increase of 0.23% compared to the same period last year. The revenue from bio-pesticides was 0.132 billion yuan, accounting for 15.30% of the revenue, a decrease of 19.56% compared to the same period last year. The revenue from water affairs operation was 2.9
Express News | Zhejiang Qianjiang Biochemical: Net income for the first half of 2024 decreased by 2.62% year-on-year.
Express News | Delivery of some vitamin products from BASF has been affected by force majeure. Concept stocks have surged and over 10 listed companies have responded to their related business layout.
Zhejiang Qianjiang Biochemical (600796.SH): Previously constructed a vitamin B2 production line with a designed capacity of 300 tons per year.
Zhejiang Qianjiang Biochemical (600796.SH) stated on the investor interaction platform on August 8th that the company previously constructed a vitamin B2 production line with a designed capacity of 300 tons/year. However, due to factors such as the low vitamin price after production and the expiration of production license, the production and sales of vitamin B2 were suspended. The company will consider resuming production based on changes in the vitamin price market, but even if production resumes, the contribution of revenue to the company's total revenue is very small based on the current vitamin B2 production capacity and market price.
No Data
No Data